A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
- PMID: 19236265
- PMCID: PMC3593193
- DOI: 10.1517/13543780802691068
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
Abstract
Vascular-disrupting strategies impair a tumor's blood vessel network, which is essential for tumor progression and metastasis. Vascular-disrupting agents (VDAs) cause a rapid and selective vascular shutdown in tumors to produce extensive secondary neoplastic cell death due to ischemia. A lead agent in this therapeutic strategy is the tubulin depolymerizing agent combretastatin-A4 phosphate (CA4P). Used alone, CA4P induces extensive necrosis in a wide variety of preclinical cancer models and significant blood flow reductions in the patient tumors. Preclinical and clinical data further indicate that CA4P can effectively be combined with chemotherapy or radiotherapy. Finally, the potential of combining VDAs with antiangiogenic therapies has shown considerable promise in preclinical models and such combinations are now beginning to be evaluated in patients.
Figures



Similar articles
-
Combretastatin A4 phosphate: a novel vascular disrupting agent.Future Oncol. 2010 Aug;6(8):1219-28. doi: 10.2217/fon.10.90. Future Oncol. 2010. PMID: 20799867 Review.
-
Combretastatin A4 phosphate: background and current clinical status.Expert Opin Investig Drugs. 2004 Sep;13(9):1171-82. doi: 10.1517/13543784.13.9.1171. Expert Opin Investig Drugs. 2004. PMID: 15330748 Review.
-
A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.Vet Comp Oncol. 2018 Dec;16(4):467-477. doi: 10.1111/vco.12402. Epub 2018 May 24. Vet Comp Oncol. 2018. PMID: 29797763
-
Combretastatin A4 phosphate.Anticancer Drugs. 2004 Mar;15(3):179-87. doi: 10.1097/00001813-200403000-00001. Anticancer Drugs. 2004. PMID: 15014350 Review.
-
Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.World J Gastroenterol. 2018 Jul 7;24(25):2710-2721. doi: 10.3748/wjg.v24.i25.2710. World J Gastroenterol. 2018. PMID: 29991876 Free PMC article.
Cited by
-
Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.Int J Mol Sci. 2020 Jul 6;21(13):4778. doi: 10.3390/ijms21134778. Int J Mol Sci. 2020. PMID: 32640548 Free PMC article.
-
Synthesis, biological evaluation, and modeling studies of 1,3-disubstituted cyclobutane-containing analogs of combretastatin A4.J Mol Struct. 2020 Jun 15;1210:128025. doi: 10.1016/j.molstruc.2020.128025. Epub 2020 May 10. J Mol Struct. 2020. PMID: 32655187 Free PMC article.
-
Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation.Diagnostics (Basel). 2020 Jan 31;10(2):78. doi: 10.3390/diagnostics10020078. Diagnostics (Basel). 2020. PMID: 32024029 Free PMC article. Review.
-
Antitumor Drug Combretastatin-A4 Phosphate Aggravates the Symptoms of Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice.Front Pharmacol. 2020 Mar 24;11:339. doi: 10.3389/fphar.2020.00339. eCollection 2020. Front Pharmacol. 2020. PMID: 32265711 Free PMC article.
-
A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.Integr Biol (Camb). 2011 Apr;3(4):375-87. doi: 10.1039/c0ib00135j. Epub 2011 Feb 14. Integr Biol (Camb). 2011. PMID: 21321746 Free PMC article.
References
-
- Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 1989;45:209–211. - PubMed
-
- Lin CM, Singh SB, Chu PS, Dempcy RO, et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol. 1988;34:200–208. - PubMed
-
- Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, LoRusso PM. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res. 2005;11:416–420. - PubMed
-
- Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 2001;21:93–102. - PubMed
-
- Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Brit J Cancer. 1999;80:57–64. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources